

# Naturopathic Anti-Tumoral Treatment & 8 Year Survival Benefit Statistics: A Single-Centre Experience

Dr. Gurdev Parmar, ND

*Integrated Health Clinic, Fort Langley, Canada*

## **Introduction:**

There is a considerable amount of research supporting the use of hyperthermia as an adjuvant treatment in oncology. Both modulated electrohyperthermia (mEHT) and fever-range whole body hyperthermia (FR-WBHT) have been added to our adjuvant treatment of various cancer types. This study will present the findings of these treatments over the past 8 years in our integrative naturopathic oncology setting. There will also be a presentation of several exceptional case studies from this dataset, which will help illustrate the process by which these treatments are incorporated into an integrative treatment approach.

## **Methods:**

mEHT was administered using the Oncotherm EHY-2000+, and FR-WBHT using the Heckel HT-2000.

## **Results:**

An examination of the data from the past 8 years will be provided. mEHT has been administered to hundreds of patients with over 35 cancer types. Data elements include patient statistics, cancer group & type, treatment(s) used, adverse events, overall survival (OS), diagnostic imaging & blood test results. We have also now provided FR-WBHT to hundreds of patients and we have collected similar data in the evaluation of this treatment's benefit. An initial analysis of this data will be provided. A Best Case Series of several exceptional case reports will also be presented.

## **Conclusion:**

mEHT and FR-WBHT are safe treatments with very few adverse events or side effects, allowing patients to maintain a high quality of life. Moreover, our initial data indicates that the addition of these therapies into an integrative oncology setting provides benefits to PFS and OS, as well as to QOL.